Literature DB >> 21180538

Ulcerative colitis: current treatment strategies and future prospects.

Sagar Garud1, Mark A Peppercorn.   

Abstract

Ulcerative colitis (UC) is a disease of unknown etiology characterized by inflammation of the mucosa and occasionally the submucosa of the colon. Conventional drug therapy for UC involves use of aminosalicylates, corticosteroids, azathioprine/6-mercaptopurine, cyclosporine and anti-tumor necrosis factor therapy. Alternative therapies include probiotics, nicotine and fish oil. Drugs like tacrolimus, rosiglitazone and Trichuris suis ova are being evaluated for use in UC patients. With the new biologic agents, new treatment options for UC continue to evolve. In this article we will discuss the conventional drugs, the alternative therapies and the management strategies according to the severity and extent of UC.

Entities:  

Keywords:  adalimumab; certolizumab pegol; sagramostin; tumor necrosis factor alpha inhibitors; ulcerative colitis

Year:  2009        PMID: 21180538      PMCID: PMC3002512          DOI: 10.1177/1756283X09102329

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  55 in total

Review 1.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.

Authors:  A Timmer; J W D McDonald; J K Macdonald
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Hepatosplenic T cell lymphoma in inflammatory bowel disease.

Authors:  Matthew Shale; Ed Kanfer; Remo Panaccione; Subrata Ghosh
Journal:  Gut       Date:  2008-07-30       Impact factor: 23.059

3.  Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis.

Authors:  C J Mulder; G N Tytgat; I T Weterman; W Dekker; P Blok; M Schrijver; H van der Heide
Journal:  Gastroenterology       Date:  1988-12       Impact factor: 22.682

4.  Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.

Authors:  C Cuffari; S Hunt; T Bayless
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

5.  6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease.

Authors:  J Maté-Jiménez; C Hermida; J Cantero-Perona; R Moreno-Otero
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-11       Impact factor: 2.566

6.  Mesalazine-associated interstitial nephritis.

Authors:  M J World; P E Stevens; M A Ashton; D J Rainford
Journal:  Nephrol Dial Transplant       Date:  1996-04       Impact factor: 5.992

7.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

Authors:  Gert Van Assche; Geert D'Haens; Maja Noman; Séverine Vermeire; Martin Hiele; Katrien Asnong; Joris Arts; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

8.  Modulation of human colonic arachidonic acid metabolism by sulfasalazine.

Authors:  C J Hawkey; N K Boughton-Smith; B J Whittle
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

9.  Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome.

Authors:  M Mogadam; W O Dobbins; B I Korelitz; S W Ahmed
Journal:  Gastroenterology       Date:  1981-01       Impact factor: 22.682

Review 10.  Azathioprine in inflammatory bowel disease, a safe alternative?

Authors:  A A Tanis
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

View more
  17 in total

Review 1.  Management of Ulcerative Colitis in the Elderly.

Authors:  Manish P Shrestha; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

Review 2.  Control of autoimmune inflammation by celastrol, a natural triterpenoid.

Authors:  Shivaprasad H Venkatesha; Steven Dudics; Brian Astry; Kamal D Moudgil
Journal:  Pathog Dis       Date:  2016-07-11       Impact factor: 3.166

3.  Increased DMT1 and FPN1 expression with enhanced iron absorption in ulcerative colitis human colon.

Authors:  Emily A Minor; Justin T Kupec; Andrew J Nickerson; Karthikeyan Narayanan; Vazhaikkurichi M Rajendran
Journal:  Am J Physiol Cell Physiol       Date:  2019-11-13       Impact factor: 4.249

Review 4.  Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults.

Authors:  Gerda C Leitner; Harald Vogelsang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

5.  Cyclosporine Therapy as a Rescue Treatment in Steroid Refractory Acute Severe Ulcerative Colitis: A Real Life Data From a Tertiary Center.

Authors:  Sami Evirgen; Raim İliaz; Filiz Akyüz; Bilger Çavuş; Suut Göktürk; Aslı Örmeci; Özlem Mutluay Soyer; Bülent Baran; Binnur Pınarbaşı; Çetin Karaca; Kadir Demir; Fatih Beşışık; Sabahattin Kaymakoğlu
Journal:  Turk J Gastroenterol       Date:  2022-06       Impact factor: 1.555

6.  A novel player: cyclosporine therapy in the management of inflammatory bowel disease.

Authors:  Simcha Weissman; Abimbola Chris-Olaiya; Tej I Mehta; Muhammad Aziz; Ali Alshati; Rani Berry; Rawish Fatima; Sindhura Kolli; Ammar Hassan; Michael A Sciarra
Journal:  Transl Gastroenterol Hepatol       Date:  2019-09-10

Review 7.  Food allergy diagnosis and therapy: where are we now?

Authors:  Aleena Syed; Arunima Kohli; Kari C Nadeau
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

8.  Association of miR-196a-2 and miR-499 variants with ulcerative colitis and their correlation with expression of respective miRNAs.

Authors:  Raju Ranjha; Naresh Kumar Meena; Abhiraman Singh; Vineet Ahuja; Jaishree Paul
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

9.  Interleukin-6 induces S100A9 expression in colonic epithelial cells through STAT3 activation in experimental ulcerative colitis.

Authors:  Min Jeoung Lee; Jin-Ku Lee; Ji Won Choi; Chang-Seok Lee; Ji Hyun Sim; Chung-Hyun Cho; Kwang-Ho Lee; Ik-Hyun Cho; Myung-Hee Chung; Hang-Rae Kim; Sang-Kyu Ye
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

10.  Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.

Authors:  Elham A Hassan; Haidi K Ramadan; Ali A Ismael; Khaled F Mohamed; Madiha M El-Attar; Ihab Alhelali
Journal:  Saudi J Gastroenterol       Date:  2017 Jul-Aug       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.